Under the agreement, National Neurovision Research Institute (NNRI) will fully fund preclinical studies and will also provide access to specialized research facilities and ocular research experts to conduct studies to evaluate the effectiveness of resolvins for specific eye diseases.
Resolvyx will provide the company’s proprietary resolvin therapeutics, including RX-10001, RX-10008, and RX-20001, for the research studies. Resolvyx will retain all rights to develop and commercialize these compounds and any discoveries that result from the collaboration.
Per Gjorstrup, chief medical officer of Resolvyx Pharmaceuticals, said: “We are extremely encouraged by the potential for resolvins to treat a number of serious eye diseases, as we have demonstrated that resolvins have a unique ability to naturally inhibit key inflammatory processes, preserve the integrity of eye tissue and promote eye tissue repair.
“We look forward to working with NNRI to continue to advance our promising ocular compounds to address serious eye diseases for which there are currently no effective treatment options.”